PIVOT-09: A phase III randomized open-label study of bempegaldesleukin (NKTR-214) plus nivolumab versus sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma (RCC)

被引：0

作者：

Tannir, Nizar M.

Agarwal, Neeraj

Pal, Sumanta K.

Cho, Daniel C.

Formiga, Maria

Guo, Jun

George, Daniel J.

Tagliaferri, Mary Ann

Singel, Stina Mui

O'Keeffe, Bridget A.

Hannah, Alison L.

Balbas, Minna

Penkov, Konstantin

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

[3] City Hope Comprehens Canc Ctr, Duarte, CA USA

[4] NYU, Perlmutter Canc Ctr, Langone Hlth, New York, NY USA

[5] AC Camargo Canc Ctr, Sao Paulo, Brazil

[6] Peking Univ, Canc Hosp & Inst, Beijing Shi, Peoples R China

[7] Duke Univ, Sch Med, Durham, NC USA

[8] Nektar Therapeut, San Francisco, CA USA

[9] Private Med Inst Euromedserv, St Petersburg, Russia

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS763

引用

页数：1

共 50 条

[1] A phase III randomized open label study comparing bempegaldesleukin (NKTR-214) plus nivolumab to sunitinib or cabozantinib (investigator's choice) in patients with previously untreated advanced renal cell carcinoma.
Tannir, Nizar M.
Agarwal, Neeraj
Pal, Sumanta K.
Formiga, Maria Nirvana
Guo, Jun
George, Daniel J.
Tagliaferri, Mary Ann
Hannah, Alison L.
Zhang, Jenny Yanzhen
O'Keeffe, Bridget A.
Cho, Daniel C.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[2] Bempegaldesleukin Plus Nivolumab Versus Sunitinib or Cabozantinib in Previously Untreated Advanced Clear Cell Renal Cell Carcinoma: A Phase III Randomized Study (PIVOT-09)
Tannir, Nizar M.
Formiga, Maria Nirvana
Penkov, Konstantin
Kislov, Nikolay
Vasiliev, Aleksandr
Skare, Nils Gunnar
Hong, Walter
Dai, Stanley
Tang, Lily
Qureshi, Anila
Zalevsky, Jonathan
Tagliaferri, Mary A.
George, Daniel
Agarwal, Neeraj
Pal, Sumanta
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (23) : 2800 - 2811
[3] Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator's choice of sunitinib or cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a phase III randomized study (PIVOT-09)
Tannir, N.
Formiga, M. N.
Agarwal, N.
Pal, S. K.
Cho, D.
George, D. J.
Hong, W.
Tang, L.
Qureshi, A.
Tagliaferri, M. A.
Zalevsky, J.
Penkov, K. D.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1433 - S1433
[4] CheckMate 214: A phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma.
Hammers, Hans J.
Plimack, Elizabeth R.
Sternberg, Cora
McDermott, David F.
Larkin, James M. G.
Ravaud, Alain
Rini, Brian I.
Sharma, Padmanee
Bhagavatheeswaran, Prabhu
Gagnier, Paul
Motzer, Robert
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[5] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
Choueiri, Toni K.
Apolo, Andrea B.
Powles, Thomas
Escudier, Bernard
Aren, Osvaldo Rudy
Shah, Amishi
Kessler, Elizabeth Riley
Hsieh, James J.
Zhang, Joshua
Simsek, Burcin
Scheffold, Christian
Motzer, Robert J.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[6] PIVOT IO 011: A phase 1/2 study of bempegaldesleukin (BEMPEG; NKTR-214) plus nivolumab (NIVO) and tyrosine kinase inhibitor (TKI) versus NIVO and TKI alone in patients (pts) with previously untreated advanced or metastatic renal cell carcinoma (mRCC).
Voss, Martin H.
Tykodi, Scott S.
Grimm, Marc-Oliver
Hammers, Hans J.
Rini, Brian I.
Tannir, Nizar M.
Qureshi, Anila H.
Tsipouri, Vicky
Hodari, Moana
Ravimohan, Shruthi
Reimers, Melissa Andrea
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[7] CA045-001: A phase Ill, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
Khushalani, Nikhil I.
Diab, Adi
Ascierto, Paolo Antonio
Larkin, James M. G.
Sandhu, Shahneen Kaur
Sznol, Mario
Koon, Henry B.
Jarkowski, Anthony
Zhou, Ming
Wang, Rui
Bajaj, Gaurav
Long, Georgina V.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[8] A phase 3, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in subjects with previously untreated metastatic renal cell carcinoma
Hammers, H.
Sternberg, C.
Mcdermott, D. F.
Larkin, J.
Ravaud, A.
Rini, B.
Sharma, P.
Bhagavatheeswaran, P.
Gagnier, P.
Motzer, R.
BJU INTERNATIONAL, 2014, 114 : 9 - 9
[9] PIVOT-10: A phase II study of bempegaldesleukin (NKTR-214) in combination with nivolumab (NIVO) in cisplatin (cis) ineligible patients with previously untreated locally advanced or metastatic urothelial cancer (mUC)
Huddart, Robert A.
Siefker-Radtke, Arlene O.
Balar, Arjun Vasant
Bilen, Mehmet Asim
Powles, Thomas
Bamias, Aristotelis
Castellano, Daniel
Khalil, Maged F.
Van der Heijden, Michiel Simon
Koshkin, Vadim S.
Pook, David William
Ozguroglu, Mustafa
Santiago, Linda
Saab, Rabih
Li, Pao-Chen
Tagliaferri, Margit Cecile
Lin, Wei
Tagliaferri, Mary Ann
Loriot, Yohann
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
[10] CheckMate 025: a randomized, open-label, phase III study of nivolumab (NIVO) versus everolimus (EVE) in advanced renal cell carcinoma (RCC)
Sharma, P.
Escudier, B.
McDermott, D. F.
George, S.
Hammers, H. J.
Srinivas, S.
Tykodi, S. S.
Sosman, J. A.
Procopio, G.
Plimack, E. R.
Castellano, D.
Gurney, H.
Donskov, F.
Bono, P.
Wagstaff, J.
Gauler, T. C.
Ueda, T.
Xu, L. A.
Waxman, I. M.
Motzer, R. J.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S708 - S708

← 1 2 3 4 5 →